Mani Inc
TSE:7730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (50), the stock would be worth ¥3 636.71 (113% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 23.5 | ¥1 706 |
0%
|
| 3-Year Average | 50 | ¥3 636.71 |
+113%
|
| 5-Year Average | 76.8 | ¥5 586.29 |
+227%
|
| Industry Average | 31.8 | ¥2 316.06 |
+36%
|
| Country Average | 22.4 | ¥1 626.05 |
-5%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Mani Inc
TSE:7730
|
168B JPY | 23.5 | 22.4 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 48.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 26.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 18 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD | 25.6 | 30.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | -25.1 | -15.8 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.7 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 33.7 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 10.3 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -115.1 | -36.5 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 14.9 |
| Median | 22.4 |
| 70th Percentile | 35 |
| Max | 736 044 589.7 |
Other Multiples
Mani Inc
Glance View
In the dynamic landscape of modern manufacturing, Mani Inc. emerges as a pivotal player, weaving together innovation and tradition in the realm of precision tools. Founded in the late 20th century, the company quickly distinguished itself by specializing in the design and production of high-quality dental and medical instruments. At its core, Mani Inc. thrives on its commitment to quality and reliability, underpinning its operations with cutting-edge technology and meticulous craftsmanship. Boasting a global presence, the company navigates a complex supply chain and adheres to stringent regulatory standards, ensuring its tools meet the diverse needs of practitioners around the world. Mani Inc. engages directly with dental professionals and healthcare institutions, building lasting relationships that are strengthened by the consistent performance and longevity of its products. Economically, Mani Inc. capitalizes on its expansive distribution network and brand loyalty to generate revenue, with a business model that focuses on both direct sales and partnerships with distributors. This approach allows the company not only to reach a wide array of international markets but also to tailor its offerings to specific regional demands. Its commitment to research and development propels innovation that further solidifies its market position, helping to safeguard against the fluctuations that often characterize the medical tools segment. By investing significantly in R&D, Mani Inc. ensures its product lineup remains at the forefront of technology and efficiency, thereby reinforcing its competitive edge in an industry where precision is paramount.
